David Henry, MD, on Anticoagulants: Expert Perspective

2015 ASH Annual Meeting

David Henry, MD, of Pennsylvania Hospital, discusses new advances with direct oral anticoagulants, or DOACs.

James Foran, MD, on Clofarabine for AML: Clinical Trial Results of ECOG-ACRIN and ALFA/Clara

James Foran, MD, of the Mayo Clinic Cancer Center, discusses two key studies on clofarabine: as a single agent for induction and postremission therapy in newly diagnosed AML, and as the basis for consolidation in nonfavorable AML (Abstracts 217 and 218).

Leukemia

Andrew D. Zelenetz, MD, PhD

Andrew D. Zelenetz, MD, PhD, on CLL: Idelalisib Plus Bendamustine and Rituximab

Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses a late-breaking abstract on the superiority of this three-drug combination compared to bendamustine and rituximab alone in patients with relapsed/refractory chronic lymphocytic leukemia (Abstract LBA5).

Multiple Myeloma

David Henry, MD

David Henry, MD, on Multiple Myeloma: Expert Perspective

David Henry, MD, of Pennsylvania Hospital, discusses the exciting developments in multiple myeloma treatment, including the three new drugs approved for the disease in November 2015.

Leukemia

Richard M. Stone, MD

Richard M. Stone, MD, on AML: Results of the RATIFY Trial

Richard M. Stone, MD, of the Dana-Farber Cancer Institute, discusses this international prospective study on the survival impact of midostaurin, a multikinase inhibitor, in newly diagnosed acute myeloid leukemia with FLT3 mutations (Abstract 6).

Leukemia

Sébastien Maury, MD

Sébastien Maury, MD, on ALL: Results of the Graall-R 2005 Study (French Language Version)

Sébastien Maury, MD, of the Hôpital Henri Mondor, discusses in French this study in which adding rituximab improved the outcome of adult patients with CD20-positive, Ph-negative B-cell precursor acute lymphoblastic leukemia (Abstract 1).

Oct

Today In Oncology

David Henry, MD, on Anticoagulants: Expert Perspective

Related Videos

James Foran, MD, on Clofarabine for AML: Clinical Trial Results of ECOG-ACRIN and ALFA/Clara

Andrew D. Zelenetz, MD, PhD, on CLL: Idelalisib Plus Bendamustine and Rituximab

David Henry, MD, on Multiple Myeloma: Expert Perspective

Richard M. Stone, MD, on AML: Results of the RATIFY Trial

Sébastien Maury, MD, on ALL: Results of the Graall-R 2005 Study (French Language Version)

Autonomous AI Triaged Urgent Suspected Skin Cancer Referrals in Real-World Implementation Study

ER-Positive HER2-Negative Advanced Breast Cancer: Giredestrant Plus Everolimus

Immune Cell Dysfunction Not Absence Defines Nonmelanoma Skin Cancer in Immunosuppressed Patients

Wildfire-Related Fine Particulate Matter Linked to Higher Mortality in Older Patients With Lung Cancer

Global Gaps in Cancer-Control Expenditure Data Identified